tiprankstipranks
Recursion Pharmaceuticals reports Q4 EPS (31c), consensus (29c)
The Fly

Recursion Pharmaceuticals reports Q4 EPS (31c), consensus (29c)

Reports Q4 revenue $13.68M, consensus $24M. "2022 was a fantastic year for Recursion where we continued to deliver on the promise of our pipeline with five clinical trial initiations, continued execution of our Bayer and Roche-Genentech partnerships, and continued to grow our proprietary data moat through our scale and accelerating capabilities across transcriptomics, digital in vivo tolerability, and chemistry," said Chris Gibson, co-founder and CEO at Recursion. "I believe that the work we have done in 2022 is setting the stage for significant value-creation in the coming 12-24 months. What is most exciting to me is the rapid uptick in the world’s curiosity around ML and AI due to advances in other industries. I think it is important to reflect on the tremendous advancements taking place around us and I believe we are best positioned to deploy similar tools across the drug discovery and development process."

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on RXRX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles